<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02281266</url>
  </required_header>
  <id_info>
    <org_study_id>ZDX-2014-05</org_study_id>
    <nct_id>NCT02281266</nct_id>
  </id_info>
  <brief_title>Thymalfasin Adjuvant Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC) After Curative Resection</brief_title>
  <official_title>Investigator Initiated Study of Thymosin in HBV-related HCC</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jia Fan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>SciClone Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety of Thymalfasin adjuvant therapy in HBV-related HCC after curative&#xD;
      resection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-center, Randomized, Controlled Clinical Trial to Evaluate the Efficacy and Safety of&#xD;
      Adjuvant Thymalfasin Therapy in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma&#xD;
      After Curative Resection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free Survival</measure>
    <time_frame>2-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence-free Survival (RFS)</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean recurrence time</measure>
    <time_frame>up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor sample immune cell counts</measure>
    <time_frame>tumor sample will be collected at baseline and when relapse</time_frame>
    <description>immune cell counts includes T cell counts(CD3, CD4, CD8), Treg count(FoxP3), Th17 cell count(IL-17), natural killer(NK) cell count(CD56), neutrophil count(CD66b), Mφ count(CD68), dendritic cell(DC) count (CD1a,CD83), MVD(CD31)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence and types of Adverse Events (AE) and serious adverse event (SAE)</measure>
    <time_frame>2-year</time_frame>
    <description>AE and SAE will be reported. The number of patients with AE and the number of patients with SAE will be calculated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of patients with abnormal laboratory value, vital signs and ECG result</measure>
    <time_frame>2-year</time_frame>
    <description>The number of patients with abnormal laboratory value, vital signs and ECG result during the study will also be calculated.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Curable Hepatitis B Virus-Related Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>treatment (T)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients of treatment arm will be administered subcutaneously Thymalfasin at dose of 1.6mg twice a week for 12 months after curative resection, followed by 12 months observation.&#xD;
Nucleoside analog plan to give to HBV DNA positive patients.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control (C)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients of control arm will be followed up for 2 years periodically after curative resection, without the investigational product (Thymalfasin) therapy.&#xD;
Nucleoside analog plan to give to HBV DNA positive patients.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>curative resection</intervention_name>
    <arm_group_label>control (C)</arm_group_label>
    <arm_group_label>treatment (T)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thymalfasin</intervention_name>
    <description>1.6mg twice a week, 12 months</description>
    <arm_group_label>treatment (T)</arm_group_label>
    <other_name>ZADAXIN</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nucleoside analog (suggest to use entecavir)</intervention_name>
    <arm_group_label>control (C)</arm_group_label>
    <arm_group_label>treatment (T)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Inclusion criteria during perioperative period&#xD;
&#xD;
          -  Male or female patients with age between 18-70 years.&#xD;
&#xD;
          -  Life expectance ≥ 3 months.&#xD;
&#xD;
          -  Diagnosis of Hepatocellular Carcinoma confirmed by Histological or Cytological&#xD;
             examination.&#xD;
&#xD;
          -  Hepatitis B history with current HBsAg positive and/or HBV DNA positive&#xD;
&#xD;
          -  Will undergo hepatic curative resection.&#xD;
&#xD;
          -  Tumor feature a. with cancer embolus b. a solitary nodule measuring between 3-8 cm or&#xD;
             2 nodule, a total combined measurement between 3-8 cm&#xD;
&#xD;
          -  East Cooperative Oncology Group performance score of 0-2&#xD;
&#xD;
          -  Normal liver function or sufficient liver function, defined as Chlid's-Pugh A&#xD;
&#xD;
        Inclusion criteria at baseline post-operation (4weeks ± 7days post-operation)&#xD;
&#xD;
          -  No documented evidence of disease recurrence with computed tomography (CT) scan and CT&#xD;
             angiography.&#xD;
&#xD;
          -  Grade A of Chlid's-Pugh score&#xD;
&#xD;
          -  hematological test white blood cell (WBC)&gt;3.5X109/L, red blood cell (RBC)&gt;30%,&#xD;
             platelet count (PLT)&gt;50,000/Ul, neutrophil (NEU)&gt;1.0X109/L, Cr&lt;1.5 mg/dl&#xD;
&#xD;
          -  signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any anti-cancer therapy, including liver transplant, transarterial Chemo-embolization&#xD;
             (TACE), image-guided tumor ablation, radiotherapy, chemotherapy, molecular targeted&#xD;
             therapy and immunotherapy, etc. prior to the liver surgery procedure.&#xD;
&#xD;
          -  Taking the hepatotoxic drug or immunosuppressant drug.&#xD;
&#xD;
          -  Invasion of portal vascular and its first branch, hepatic duct and its first branch,&#xD;
             inferior vena cava and hepatic vein.&#xD;
&#xD;
          -  Organ transplant recipient.&#xD;
&#xD;
          -  Extra-hepatic organs and lymph node metastasis.&#xD;
&#xD;
          -  Uncontrolled Hypertension, unstable angina within 3 months, congestive heart failure&#xD;
             (New York Heart Association (NYHA) Class II or greater), history of myocardial&#xD;
             infarction within 6 months prior to randomization and severe arrhythmia need to be&#xD;
             treated.&#xD;
&#xD;
          -  History of malignancy other than a successfully treated non-metastatic cutaneous&#xD;
             squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix&#xD;
&#xD;
          -  Known human immune deficiency virus (HIV) infection&#xD;
&#xD;
          -  hepatitis C virus (HCV) infection&#xD;
&#xD;
          -  History of stroke or transient ischemic attack within 6 months prior to randomization&#xD;
&#xD;
          -  Active or untreated central nervous system (CNS) metastasis&#xD;
&#xD;
          -  History of clinically significant drug or alcohol abuse&#xD;
&#xD;
          -  Prior treatment with immunomodulator (e.g. interferon, Thymalfasin) or traditional&#xD;
             Chinese medicine within 30 days prior to randomization&#xD;
&#xD;
          -  Know postoperative complications (e.g. infection, bleeding, bile leak) at baseline&#xD;
&#xD;
          -  Known allergic reaction to the investigational product and its excipient.&#xD;
&#xD;
          -  Female subjects who are pregnant or breast-feeding or considering becoming pregnant&#xD;
             during the study.&#xD;
&#xD;
          -  The investigator considers the subject, for any reason, to be unacceptable for study&#xD;
             participation.&#xD;
&#xD;
          -  Participating in other clinical trials of the drug or medical device within 30 days&#xD;
             prior to randomization.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <study_first_submitted>October 15, 2014</study_first_submitted>
  <study_first_submitted_qc>October 30, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 2, 2014</study_first_posted>
  <last_update_submitted>November 20, 2014</last_update_submitted>
  <last_update_submitted_qc>November 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Jia Fan</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Entecavir</mesh_term>
    <mesh_term>Thymalfasin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

